New Drug Development Services
Syngeneic models
Syngeneic mouse models involve the use of immunocompetent mice to establish syngeneic transplantation models of murine-origin tumors. Due to the completely natural immune system in these mice, they serve as an ideal choice for testing various immunotherapies. This model allows for the evaluation of immune responses that closely resemble clinical scenarios.
● Our platform boasts access to over 60 different tumor cell lines, covering a wide spectrum of cancer types and subtypes. This diverse collection enables you to select the most suitable cell lines for your research, ensuring relevance to your specific area of study.
● Our team of researchers possesses extensive operational experience, ensuring high-quality execution of experiments.
● Our cells undergo internal validation to guarantee their quality and stability, providing a reliable foundation for research.
● Our platform boasts strong immunological analysis capabilities with a ready stock of various mouse flow cytometry antibodies. We can perform PK/PD analyses at any time to support pharmacological efficacy experiments.
● Our scientific team is composed of PhDs with extensive industry experience. They are dedicated to providing scientific support for every project. Whether it's designing experiments, troubleshooting, or offering guidance on data interpretation, our experts are here to ensure your research is on the right track.
● We offer tailored experimental support, designing experiments according to your research needs to ensure optimized experimental protocols that align with your specific objectives.
| Types | Cell Line Name | Synonyms | Disease (English) | Species of origin |
| Hemato>Leukemia | C1498 | Mouse leukemia | Mus musculus>C57BL/6 | |
| Solid>Digestive system>Digestive tract>Colon | MC-38 | MCA-38; MCA 38; MCA38; MC38; Mouse Colon 38; Murine Carcinoma-38; Colon 38; Colon-38; Colon38; C38 | Mouse colon adenocarcinoma | Mus musculus>C57BL/6 |
| Solid>Skin | B16-F10 | B16/F10; B16 F10; B16F10; B16 melanoma F10 | Mouse melanoma | Mus musculus>C57BL/6 |
| Solid>Male reproductory system>Testis | MLTC-1 | mLTC-1; Murine Leydig Tumor Cell line-1 | Mouse leydig cell tumor | Mus musculus>C57BL/6 |
| Solid>Female reproductory system>Ovary | ID8-luc | ID8luc2 | Mus musculus>C57BL/6 | |
| Solid>Digestive system>Digestive tract>Stomach | MFC | Mouse Forestomach Carcinoma | Mouse gastric carcinoma | Mus musculus |
| Solid>Digestive system>Digestive tract>Colorectal | MC38-C17 | MC38-C17 | Mouse colon adenocarcinoma | Mus musculus>C57BL/6 |
| Solid>Digestive system>Digestive tract>Colorectal | MC38-FR | MC38-FR | Mouse colon adenocarcinoma | Mus musculus>C57BL/6 |
| Solid>Digestive system>Digestive tract>Colorectal | MC38(2) | MC38(2) | Mouse colon adenocarcinoma | Mus musculus>C57BL/6 |
| Solid>Digestive system>Digestive tract>Colorectal | CT26 | CT-26; CT 26; Colon Tumor 26 | Mouse colon adenocarcinoma | Mus musculus>BALB/c |
| Solid>Digestive system>Digestive tract>Colorectal | CT26-C17 | CT26-C17 | Mouse colon adenocarcinoma | Mus musculus>BALB/c |
| Solid>Digestive system>Liver and billiary tract>Hepatic | Hepa1-6 | HEPA 1-6; Hepa-1-6; Hepa1-6 | Hepatocellular carcinoma of the mouse | Mus musculus>C57L |
| Solid>Digestive system>Liver and billiary tract>Hepatic | Hepa-1c1c7 | Hepa 1c1c7; Hepa1c1c7; Hepa 1-clc7 | Hepatocellular carcinoma of the mouse | Mus musculus>C57L |
In this study, we tested an immunomodulatory agent based on traditional herbal medicine. In the MC38 cell line, this treatment regimen demonstrated efficacy similar to PD-1 therapy. However, TIL analysis revealed that the mechanism of action of this treatment differs from that of PD-1 therapy. Specifically, it reduces tumor burden in tumor-bearing mice by significantly decreasing M2 macrophage infiltration within TILs.
Case
